Cochrane · systematic review · CD011943
Mirtazapine adjunct for people with schizophrenia
Perry, LA, Ramson, D, Stricklin, S · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 3 · 42.9%Low 1 · 14.3%Moderate 1 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Mirtazapine adjunct versus placebo adjunct
Population: schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: specific negative symptoms ‐ clinically important change (no important response) Mirtazapine adjunct vs placebo adjunct | RR 0.81 [0.57, 1.14] | 1 study · 20 participants | Very low Downgraded: risk of bias |
Mental state: overall mental state ‐ clinically important change* Mirtazapine adjunct vs placebo adjunct | RR 0.69 [0.51, 0.92] | 2 studies · 77 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Leaving the study early for any reason Mirtazapine adjunct vs placebo adjunct | RR 1.03 [0.64, 1.66] | 9 studies · 310 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Global state: average endpoint score (CGI severity, high = poor)* Mirtazapine adjunct vs placebo adjunct | no estimate extracted | 1 study · 39 participants | Very low Downgraded: risk of bias |
Quality of life: clinically important change Mirtazapine adjunct vs placebo adjunct | no estimate extracted | NR | No studies |
Service utilisation: number of days in hospital Mirtazapine adjunct vs placebo adjunct | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal ‐ clinically important change akathisia Mirtazapine adjunct vs placebo adjunct | RR 0.33 [0.2, 0.52] | 2 studies · 86 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |